低剂量利伐沙班联合阿司匹林在老年外周动脉疾病血运重建患者中的应用:VOYAGER PAD 试验分析
VOYAGER 试验的二次分析评估了利伐沙班 2.5 mg 每日两次联合阿司匹林 100 mg 每日一次在老年(≥75 岁)外周动脉疾病(PAD)下肢血运重建(LER)后的疗效与安全性。6564 例随机患者中 1330 例(20%)>75 岁,主要疗效终点和 TIMI 大出血的 3 年累积发生率在老年组均更高,但利伐沙班疗效与安全性不受年龄影响(交互 P 分别为 0.83 和 0.38)。结论提示低剂量利伐沙班联合阿司匹林在 PAD 血运重建后应考虑使用,无论年龄。
要点
- ≥75 岁 PAD 患者 LER 后缺血与出血风险均升高,但利伐沙班疗效与安全性不受年龄影响。
- 老年组绝对获益(主要终点绝对风险降低 3.8%,NNT=26)超过绝对风险(TIMI 大出血绝对风险增加 0.81%,NNH=123)。
- 颅内出血与致命性出血在 >75 岁患者中未见增加(利伐沙班 2 例 vs 安慰剂 8 例)。
核心结论
- ≥75 岁 PAD 患者 LER 后缺血与出血风险均升高,但低剂量利伐沙班联合阿司匹林未见大出血、颅内或致命性出血的额外危害,且绝对获益数值上更大。
- 提示 PAD 血运重建后应考虑低剂量利伐沙班联合阿司匹林,无论年龄。
研究设计与样本
- VOYAGER 试验的二次分析,评估利伐沙班 2.5 mg 每日两次联合阿司匹林 100 mg 每日一次在老年(≥75 岁)PAD 下肢血运重建后患者中的疗效与安全性。
- 共 6564 例随机患者,其中 1330 例(20%)>75 岁;主要疗效终点为急性肢体缺血、大截肢、心肌梗死、缺血性卒中或心血管死亡的复合终点;主要安全性终点为 TIMI 大出血,按预设 75 岁年龄切点分析。
主要发现
- 老年 vs 非老年患者主要疗效终点 3 年 Kaplan-Meier 累积发生率分别为 23.4% vs 19.0%,安全性终点分别为 3.5% vs 1.5%。
- 利伐沙班疗效(交互 P=0.83)与安全性(交互 P=0.38)不受年龄影响。
- 颅内出血与致命性出血联合在 >75 岁患者中未增加(利伐沙班 2 例 vs 安慰剂 8 例)。
- 总体获益(主要终点绝对风险降低 3.8%,NNT=26)超过风险(TIMI 大出血绝对风险增加 0.81%,NNH=123)。
关键数值与推荐
- 主要疗效终点 3 年累积发生率:老年组 23.4%,非老年组 19.0%。
- 主要安全性终点(TIMI 大出血)3 年累积发生率:老年组 3.5%,非老年组 1.5%。
- 主要终点绝对风险降低 3.8%,NNT=26;TIMI 大出血绝对风险增加 0.81%,NNH=123。
临床怎么用
- 对于 ≥75 岁 PAD 患者行下肢血运重建后,可考虑低剂量利伐沙班(2.5 mg 每日两次)联合阿司匹林(100 mg 每日一次)治疗。
- 治疗决策时应综合评估缺血与出血风险,但年龄本身不应作为排除联合抗栓治疗的理由。
局限性
- 本文为 VOYAGER 试验的二次分析,结果需谨慎解读。
- 老年亚组样本量相对较小(1330 例),可能影响统计效能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: In this secondary analysis of the VOYAGER trial, rivaroxaban 2.5 mg twice/day plus aspirin 100 mg/day was assessed in older adults. Advanced age is associated with elevated bleeding risk and unfavourable net benefit for dual antiplatelet therapy in chronic coronary artery disease. The risk-benefit of low-dose rivaroxaban in patients ≥75 years with peripheral artery disease (PAD) after lower extremity revascularization (LER) has not been described. METHODS AND RESULTS: The primary endpoint was a composite of acute limb ischaemia, major amputation, myocardial infarction, ischaemic stroke, or cardiovascular death. The principal safety outcome was thrombolysis in myocardial infarction (TIMI) major bleeding analysed by the pre-specified age cut-off of 75 years. Of 6564 patients randomized, 1330 (20%) were >75 years. Absolute 3-year Kaplan-Meier cumulative incidence rates for primary efficacy (23.4% vs. 19.0%) and safety (3.5% vs. 1.5%) endpoints were higher in elderly vs. non-elderly patients. Efficacy of rivaroxaban (P-interaction 0.83) and safety (P-interaction 0.38) was consistent irrespective of age. The combination of intracranial and fatal bleeding was not increased in patients >75 years (2 rivaroxaban vs. 8 placebo). Overall, benefits (absolute risk reduction 3.8%, number needed to treat 26 for the primary endpoint) exceeded risks (absolute risk increase 0.81%, number needed to harm 123 for TIMI major bleeding). CONCLUSION: Patients ≥75 years with PAD are at both heightened ischaemic and bleeding risk after LER. No excess harm with respect to major, intracranial or fatal bleeding was seen in older patients yet numerically greater absolute benefits were observed. This suggests that low-dose rivaroxaban combined with aspirin should be considered in PAD after LER regardless of age.
引用
- Krantz MJ, Debus SE, Hsia J, et al. Low-dose rivaroxaban plus aspirin in older patients with peripheral artery disease undergoing acute limb revascularization: insights from the VOYAGER PAD trial. Eur Heart J. 2021. PMID: 34430972. doi:10.1093/eurheartj/ehab408
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。